{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:57:48Z","timestamp":1792519068122,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007480","name":"Universidad de Castilla-La Mancha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejphar.2026.178560","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:55:20Z","timestamp":1768582520000},"page":"178560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Safety of metformin in chronic kidney disease and type 2 diabetes mellitus: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"1015","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3470-1724","authenticated-orcid":false,"given":"Silvana","family":"Pati\u00f1o-Cardona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1154-8752","authenticated-orcid":false,"given":"Carlos","family":"Pascual-Morena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-4331","authenticated-orcid":false,"given":"Irene","family":"Sequ\u00ed-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6176-1618","authenticated-orcid":false,"given":"Celia","family":"\u00c1lvarez-Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3991-3593","authenticated-orcid":false,"given":"H\u00e9ctor","family":"Mart\u00ednez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8484-4635","authenticated-orcid":false,"given":"Mar","family":"de Miguel-Brox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7468-5626","authenticated-orcid":false,"given":"Susana","family":"Priego-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6121-7893","authenticated-orcid":false,"given":"Vicente","family":"Mart\u00ednez-Vizca\u00edno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178560_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12933-025-02643-6","article-title":"The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study","volume":"24","author":"Agur","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2026.178560_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.ackd.2019.08.004","article-title":"Toxicity of metformin and hypoglycemic therapies","volume":"27","author":"Akhter","year":"2020","journal-title":"Adv. Chron. Kidney Dis."},{"key":"10.1016\/j.ejphar.2026.178560_bib3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejphar.2026.178560_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101517","article-title":"Mechanisms of action of metformin in type 2 diabetes: effects on mitochondria and leukocyte-endothelium interactions","volume":"34","author":"Apostolova","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2026.178560_bib5","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2026.178560_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2026.178560_bib7","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.119.040144","article-title":"Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial","volume":"140","author":"Bergmark","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2026.178560_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-021-01289-4","article-title":"Variability of risk factors and diabetes complications","volume":"20","author":"Ceriello","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2026.178560_bib9","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.13642","article-title":"Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease","volume":"21","author":"Charytan","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2026.178560_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ph15040442","article-title":"A clinical perspective of the multifaceted mechanism of metformin in diabetes, infections, cognitive dysfunction, and cancer","volume":"15","author":"Chow","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2026.178560_bib11","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/dom.14313","article-title":"Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials","volume":"23","author":"Clegg","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2026.178560_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ejphar.2026.178560_bib13","doi-asserted-by":"crossref","first-page":"9376","DOI":"10.7150\/thno.64706","article-title":"Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function","volume":"11","author":"Ding","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2026.178560_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ph14020122","article-title":"The current and potential therapeutic use of metformin-the good old drug","volume":"14","author":"Drzewoski","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejphar.2026.178560_bib15","series-title":"Metformin-Associated Lactic Acidosis (MALA)","author":"Dyatlova","year":"2025"},{"key":"10.1016\/j.ejphar.2026.178560_bib16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2026.178560_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41574-020-0355-7","article-title":"Pancreatic \u03b2-cells in type 1 and type 2 diabetes mellitus: different pathways to failure","volume":"16","author":"Eizirik","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejphar.2026.178560_bib18","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2337\/dc13-3023","article-title":"Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study","volume":"37","author":"Eppenga","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2026.178560_bib19","article-title":"Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function: recommendations for patients with kidney impairment updated in product information","year":"2016","journal-title":"European Medicines Agency EMA\/603690"},{"key":"10.1016\/j.ejphar.2026.178560_bib21","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1056\/NEJMra1602972","article-title":"FDA regulation of prescription drugs","volume":"376","author":"Gassman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178560_bib57","first-page":"203","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global Burden of disease study 2021, 2023","volume":"402","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178560_bib23","first-page":"1","article-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019","journal-title":"Cochrane Handb. Syst. Rev. Intervent."},{"key":"10.1016\/j.ejphar.2026.178560_bib24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.ejphar.2026.178560_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.559446","article-title":"Metformin use and risk of all-cause mortality and cardiovascular events in patients with chronic kidney Disease-A systematic review and meta-analysis","volume":"11","author":"Hu","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ejphar.2026.178560_bib26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(15)00123-0","article-title":"Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study","volume":"3","author":"Hung","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2026.178560_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.23876\/j.krcp.20.222","article-title":"Metformin use and cardiovascular outcomes in patients with diabetes and chronic kidney disease: a nationwide cohort study","volume":"40","author":"Kim","year":"2021","journal-title":"Kidney Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2026.178560_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/heartjnl-2016-309685","article-title":"Graphics and statistics for cardiology: data visualisation for meta-analysis","volume":"103","author":"Kiran","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2026.178560_bib29","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2337\/dc19-0936","article-title":"The long-term effects of metformin on patients with type 2 diabetic kidney disease","volume":"43","author":"Kwon","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2026.178560_bib30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.ajkd.2024.08.012","article-title":"Stopping versus continuing metformin in patients with advanced CKD: a nationwide Scottish target trial emulation study","volume":"85","author":"Lambourg","year":"2025","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2026.178560_bib31","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40620-015-0258-1","article-title":"Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions","volume":"29","author":"Langer","year":"2016","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ejphar.2026.178560_bib32","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamainternmed.2018.0292","article-title":"Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study","volume":"178","author":"Lazarus","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ejphar.2026.178560_bib33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3389\/fphys.2018.01039","article-title":"Molecular mechanisms of metformin for diabetes and cancer treatment","volume":"9","author":"Li","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2026.178560_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ph18010095","article-title":"Role of metformin in preventing new-onset chronic kidney disease in patients with type 2 diabetes mellitus","volume":"18","author":"Lin","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejphar.2026.178560_bib35","first-page":"7","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.ejphar.2026.178560_bib36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ejphar.2026.178560_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251810222","article-title":"Novel insights into diabetic kidney disease","volume":"25","author":"M\u0142ynarska","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178560_bib38","first-page":"3997","article-title":"Diabetic kidney disease: from physiology to therapeutics","volume":"592","author":"Mora-Fern\u00e1ndez","year":"2014","journal-title":"J. Physiol. (Paris)"},{"key":"10.1016\/j.ejphar.2026.178560_bib39","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/dom.14226","article-title":"Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes","volume":"23","author":"Neuen","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2026.178560_bib40","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2026.178560_bib41","article-title":"Effect of Coenzyme Q10 supplementation on lipid and glycaemic profiles: an umbrella review","volume":"11","author":"Pati\u00f1o-Cardona","year":"2024","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.ejphar.2026.178560_bib42","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1055\/a-1018-9078","article-title":"Definition, classification and diagnosis of diabetes mellitus","volume":"127","author":"Petersmann","year":"2019","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.ejphar.2026.178560_bib43","first-page":"21","article-title":"Managing therapy and adverse effects with antihyperglycemic agents: a focus on metformin and acarbose","volume":"17","author":"Phillips","year":"1997","journal-title":"Pharm. Pract. Manag. Q."},{"key":"10.1016\/j.ejphar.2026.178560_bib44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bbrc.2010.01.119","article-title":"Metformin induces suppression of NAD(P)H oxidase activity in podocytes","volume":"393","author":"Piwkowska","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2026.178560_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5455\/medarh.2022.76.297-300","article-title":"Lactic acidosis associated with metformin in patients with diabetic kidney disease","volume":"76","author":"Rahman","year":"2022","journal-title":"Med. Arch."},{"key":"10.1016\/j.ejphar.2026.178560_bib46","first-page":"1","article-title":"Can metformin exert as an active drug on endothelial dysfunction in diabetic subjects?","volume":"9","author":"Salvatore","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2026.178560_bib47","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2024.10.004","article-title":"Metformin in people with diabetes and advanced CKD: should we dare?","author":"Shin","year":"2025","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2026.178560_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111454","article-title":"Mechanism and application of metformin in kidney diseases: an update","volume":"138","author":"Song","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2026.178560_bib49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2026.178560_bib50","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2026.178560_bib51","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2026.178560_bib52","doi-asserted-by":"crossref","DOI":"10.1530\/REM-23-0015","article-title":"Metformin and its redox-related mechanisms of action in type 2 diabetes","author":"Vezza","year":"2023","journal-title":"Redox Experiment. Med."},{"key":"10.1016\/j.ejphar.2026.178560_bib53","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178560_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/ph15091140","article-title":"Attenuated risk association of end-stage kidney disease with metformin in type 2 diabetes with eGFR categories 1-4","volume":"15","author":"Yang","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejphar.2026.178560_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102568","article-title":"Clinical outcomes following discontinuation of metformin in patients with type 2 diabetes and advanced chronic kidney disease in Hong Kong: a territory-wide, retrospective cohort and target trial emulation study","volume":"71","author":"Yang","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejphar.2026.178560_bib56","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat. Rev. Endocrinol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926000427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926000427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:43:37Z","timestamp":1773981817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926000427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"alternative-id":["S0014299926000427"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178560","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of metformin in chronic kidney disease and type 2 diabetes mellitus: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178560"}}